As Boston Scientific (BSX) Valuation Rose, Pura Vida Investments Has Decreased Its Stake by $891.03 Million; As Abbott Laboratories (ABT) Valuation Declined, Smith Chas P & Associates Pa Cpas Cut Position

January 16, 2018 - By Louis Casey

Pura Vida Investments Llc decreased its stake in Boston Scientific Corp (BSX) by 7.26% based on its latest 2017Q3 regulatory filing with the SEC. Pura Vida Investments Llc sold 30,546 shares as the company’s stock rose 4.02% with the market. The institutional investor held 390,000 shares of the medical and dental instruments company at the end of 2017Q3, valued at $11.38B, down from 420,546 at the end of the previous reported quarter. Pura Vida Investments Llc who had been investing in Boston Scientific Corp for a number of months, seems to be less bullish one the $37.71B market cap company. The stock increased 0.11% or $0.03 during the last trading session, reaching $27.46. About 8.75 million shares traded. Boston Scientific Corporation (NYSE:BSX) has risen 19.12% since January 16, 2017 and is uptrending. It has outperformed by 2.42% the S&P500.

Smith Chas P & Associates Pa Cpas decreased its stake in Abbott Laboratories (ABT) by 40.62% based on its latest 2017Q3 regulatory filing with the SEC. Smith Chas P & Associates Pa Cpas sold 14,869 shares as the company’s stock declined 3.42% while stock markets rallied. The institutional investor held 21,733 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $1.16 million, down from 36,602 at the end of the previous reported quarter. Smith Chas P & Associates Pa Cpas who had been investing in Abbott Laboratories for a number of months, seems to be less bullish one the $102.42B market cap company. The stock decreased 0.19% or $0.11 during the last trading session, reaching $58.84. About 6.32M shares traded or 6.93% up from the average. Abbott Laboratories (NYSE:ABT) has risen 15.90% since January 16, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on January, 24 before the open. They expect $0.73 EPS, up 12.31% or $0.08 from last year’s $0.65 per share. ABT’s profit will be $1.27B for 20.15 P/E if the $0.73 EPS becomes a reality. After $0.66 actual EPS reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 10.61% EPS growth.

Investors sentiment decreased to 0.87 in Q3 2017. Its down 0.01, from 0.88 in 2017Q2. It turned negative, as 47 investors sold ABT shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. Villere St Denis J & Company Limited Liability Company has 0.82% invested in Abbott Laboratories (NYSE:ABT) for 262,010 shares. Investec Asset Mgmt has 248,244 shares for 0.06% of their portfolio. Lipe Dalton reported 1,980 shares. Insight Cap Research And Mgmt has invested 1.1% in Abbott Laboratories (NYSE:ABT). 225,000 are held by United Fire Gp. Acg Wealth stated it has 8,341 shares or 0.08% of all its holdings. Cullinan Assocs reported 1.1% of its portfolio in Abbott Laboratories (NYSE:ABT). Kopp Advisors has invested 0.19% of its portfolio in Abbott Laboratories (NYSE:ABT). Financial Bank Of The Ozarks reported 16,667 shares stake. Osborne Cap Management accumulated 187,499 shares. Df Dent & Company Inc, Maryland-based fund reported 11,066 shares. South Texas Money Mgmt Ltd holds 10,569 shares. Aspiriant Limited Liability Corp stated it has 0.18% in Abbott Laboratories (NYSE:ABT). Condor Cap Mngmt reported 0.74% of its portfolio in Abbott Laboratories (NYSE:ABT). Fairview Cap Invest Mngmt Ltd Llc holds 0.02% or 5,433 shares in its portfolio.

Since August 1, 2017, it had 0 buys, and 6 sales for $22.86 million activity. Another trade for 2,000 shares valued at $98,323 was sold by Bracken Sharon J. The insider Fussell Stephen R sold 196,550 shares worth $9.73 million. Contreras Jaime had sold 52,700 shares worth $2.74 million.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 92 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Equal-Weight” rating given on Thursday, October 19 by Morgan Stanley. The stock of Abbott Laboratories (NYSE:ABT) has “Hold” rating given on Thursday, August 31 by BMO Capital Markets. Jefferies maintained it with “Buy” rating and $49 target in Thursday, July 14 report. Jefferies maintained the stock with “Buy” rating in Thursday, August 4 report. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Deutsche Bank on Friday, July 21. The stock has “Buy” rating by Stifel Nicolaus on Friday, September 22. As per Tuesday, September 13, the company rating was maintained by Jefferies. Citigroup maintained Abbott Laboratories (NYSE:ABT) rating on Thursday, October 19. Citigroup has “Neutral” rating and $5 target. The company was maintained on Thursday, July 23 by Stifel Nicolaus. The stock has “Market Perform” rating by William Blair on Friday, January 29.

Investors sentiment increased to 1.04 in Q3 2017. Its up 0.01, from 1.03 in 2017Q2. It improved, as 33 investors sold BSX shares while 166 reduced holdings. 43 funds opened positions while 164 raised stakes. 1.21 billion shares or 1.08% less from 1.22 billion shares in 2017Q2 were reported. Private Trust Na holds 47,737 shares. North Carolina-based Piedmont Invest Advisors Ltd has invested 0.18% in Boston Scientific Corporation (NYSE:BSX). Cibc Asset Mngmt stated it has 133,177 shares. Eaton Vance Mngmt owns 3.38 million shares. Pub Employees Retirement Sys Of Ohio invested 0.15% in Boston Scientific Corporation (NYSE:BSX). Alphaone Investment Svcs Limited Liability Company holds 0.02% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 2,766 shares. Northwestern Mutual Wealth Management Com holds 0% or 23,354 shares. Moreover, Fil Limited has 0.14% invested in Boston Scientific Corporation (NYSE:BSX). 10,000 were reported by Thompson Siegel & Walmsley Ltd Liability. Natl Pension Ser, Korea-based fund reported 1.17M shares. Moreover, S&Co Inc has 0.7% invested in Boston Scientific Corporation (NYSE:BSX). New York-based Bnp Paribas Arbitrage has invested 0.06% in Boston Scientific Corporation (NYSE:BSX). Hsbc Hldg Public Limited reported 0.06% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Aviva Public Limited holds 862,388 shares. Hightower Advsr Limited Liability reported 0% in Boston Scientific Corporation (NYSE:BSX).

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on February, 1. They expect $0.34 EPS, up 13.33% or $0.04 from last year’s $0.3 per share. BSX’s profit will be $466.89 million for 20.19 P/E if the $0.34 EPS becomes a reality. After $0.31 actual EPS reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts 9.68% EPS growth.

Pura Vida Investments Llc, which manages about $223.00M and $199.58 billion US Long portfolio, upped its stake in Arena Pharmaceuticals Inc by 76,700 shares to 111,700 shares, valued at $2.85B in 2017Q3, according to the filing. It also increased its holding in Edwards Lifesciences Corp (Call) (NYSE:EW) by 5,000 shares in the quarter, for a total of 35,000 shares, and has risen its stake in Baxter Intl Inc (Put) (NYSE:BAX).

Among 29 analysts covering Boston Scientific Corporation (NYSE:BSX), 23 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. Boston Scientific Corporation had 83 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, October 31 by SunTrust. As per Thursday, August 31, the company rating was maintained by Needham. Wedbush maintained the stock with “Neutral” rating in Friday, July 29 report. As per Thursday, July 27, the company rating was maintained by BMO Capital Markets. Jefferies maintained Boston Scientific Corporation (NYSE:BSX) on Friday, July 28 with “Hold” rating. The rating was maintained by Needham on Thursday, June 22 with “Buy”. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Buy” rating by BMO Capital Markets on Thursday, August 31. The stock has “Buy” rating by Needham on Friday, April 28. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Buy” rating by BTIG Research on Sunday, September 6. Oppenheimer maintained the stock with “Hold” rating in Wednesday, August 9 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: